Showing results (561-570 of 654) with videos related to

Sort By:
Pageof 66
The Lancet. Diabetes & Endocrinology|June 16, 2017
Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trialJohn R Petrie, Nishi Chaturvedi, Ian Ford, et al.
Circulation|November 13, 2020
Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular DiseaseJohn J V McMurray, David C Wheeler, Bergur V Stefánsson, et al.
Diabetes & Vascular Disease Research|October 20, 2022
Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosisElisabeth B Stougaard, Peter L Kristensen, Urd Kielgast, et al.
BMC Nephrology|September 10, 2016
Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysisGemma Currie, Alison H M Taylor, Toshiro Fujita, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 19, 2025
Comparing CKD populations with T1D and T2D: a perspective based on the FINE-ONE and FIDELITY populationsHiddo J L Heerspink, Rajiv Agarwal, Antonio J Amor, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|June 6, 2026
Vitamin K status and vascular health in a general populationJulie Aaberg Lauridsen, Camilla Friis Bryde Nielsen, Line Lund Kårhus, et al.
Clinical Pharmacology and Therapeutics|July 27, 2022
Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long-Term Response to Atrasentan in Patients With Diabetic Kidney DiseaseJ David Smeijer, Jeroen V Koomen, Donald E Kohan, et al.
Lancet (London, England)|September 28, 2012
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysisCaroline S Fox, Kunihiro Matsushita, Mark Woodward, et al.
Diabetes Research and Clinical Practice|October 7, 2023
Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trialHiddo J L Heerspink, Andreas L Birkenfeld, David Z I Cherney, et al.
Cardiovascular Diabetology|August 31, 2025
Left ventricular ejection fraction reserve and its association with myocardial perfusion, coronary calcification, and strain in type 2 diabetes without overt cardiovascular diseaseAdam Chebli, Ida K B Rasmussen, Anne-Cathrine Skriver-Møller, et al.
Pageof 66